Igor Mochalkin

Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers

Sheng-Bin Peng, James R. Henry, Michael D. Kaufman et al. · Cancer Cell · 2015 · 305 citations · Full text

Ly3009120 Leads, Raf Isoforms, Medicine +8

Large-Scale Assessment of Binding Free Energy Calculations in Active Drug Discovery Projects

Christina Schindler, Hannah M. Baumann, Andreas Blum et al. · Journal of Chemical Information and Modeling · 2020 · 292 citations

A model of fibrin formation based on crystal structures of fibrinogen and fibrin fragments complexed with synthetic peptides

Zhe Yang, Igor Mochalkin, Russell F. Doolittle · Proceedings of the National Academy of Sciences · 2000 · 202 citations · Full text

Protein Assembly, Peptide Engineering, Molecular Biology +20

Oncogenic <i>BRAF</i> Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120

Shih-Hsun Chen, Youyan Zhang, Robert D. Van Horn et al. · Cancer Discovery · 2016 · 168 citations

A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore

J. Richard Miller, Steve Dunham, Igor Mochalkin et al. · Proceedings of the National Academy of Sciences · 2009 · 159 citations · Full text

Drug Target, Bioorganic Chemistry, Antimicrobial Chemotherapy +19